Raykov Rosty has demonstrated a clear selling bias in their trading activity involving Fennec Pharmaceuticals (FENC), with no recent purchases recorded. Over 23 transactions, Rosty has sold a total of $753,339.88 worth of FENC shares while buying only $214,644.50 worth, indicating a net reduction in their position. The selling has been consistent, with nine recent transactions between July 2025 and March 2026, including a $84,260.44 sale on March 2, 2026, and an $80,308.24 sale on February 2, 2026. The pattern suggests a methodical approach, with sales often occurring in the first week of each month, accompanied by smaller "M"-coded transactions—likely option-related—such as a $38,215.1 transaction on March 2, 2026.
Notably, Rosty’s sales have remained substantial, with individual transactions frequently exceeding $75,000, including an $81,000 sale on November 5, 2025, and a $97,800 sale on October 6, 2025. The absence of any recent buys, coupled with the recurring monthly disposals, points to a sustained divestment from FENC. While the filings do not specify Rosty’s role at the company, the transactions reflect a deliberate shift away from holding the stock, with no indication of accumulation over the observed period. The activity is confined solely to FENC, with no trades in other securities disclosed in the filings.
AI-assisted summary